HC Wainwright & Co. Initiates Coverage On Vyant Bio with Buy Rating, Announces Price Target of $5
HC Wainwright & Co. analyst Edward White initiates coverage on Vyant Bio (NASDAQ:VYNT) with a Buy rating and announces Price Target of $5.
12 Health Care Stocks Moving In Friday’s Pre-Market Session
Gainers
Biomerica (NASDAQ:BMRA) stock increased by 43.11% to $6.44 during Friday's pre-market session. The market value of their outstanding shares is at $80.5 million.
3 Penny Stocks Insiders Are Buying
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
20 Stocks Moving in Friday’s Pre-Market Session
Gainers
Cellect Biotechnology Ltd. (NASDAQ: APOP) rose 59.5% to $8.77 in pre-market trading after the company announced the ApoGraft bone marrow transplantation of the first patient in the US.
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 155 companies achieved new lows for the year.
Vyant Bio, Cyclica Announce Strategic Collaboration To Identify Compounds To Treat CDKL5 Deficiency Disorder
Vyant Bio, Inc., (NASDAQ:VYNT), a leading biotech company discovering new therapeutics for neurological diseases and hard-to-treat cancers, and Cyclica, Inc., the partner of choice for data driven drug
Stocks That Hit 52-Week Lows On Wednesday
Wednesday morning, 136 companies reached new 52-week lows.